Drug Discovery Opinion

Globally, around 200 million people are infected with Hepatitis C virus (HCV). Infection generally leads to chronic liver disease, albeit over a period of decades, which can lead to cirrhosis, hepatocellular carcinoma and liver failure. Current treatment, a combination of pegylated interferon-α and ribavirin, is only effective in 50-85% of patients, dependent on viral genotype. Not surprisingly, much effort is being expended to identify new therapeutic interventions.

Study of the viral lifecycle has been difficult in the past since serum-derived HCV (sHCV) replicates poorly in primary human hepatocytes and hepatoma cells in vitro. Surrogate systems have been developed, however, that have enabled reproduction of all steps of the HCV replication cycle, including cell entry (recently reviewed).

Viral cell entry is still incompletely understood, but a new study from researchers at the University of Rennes 1 has identified host kinases involved in HCV infectivity. Using a small-interfering RNA (siRNA) library, the scientists have shown that knock-down of phosphatidylinositol 4-kinase type III-α (PI4KIIIα) prevents infection by either HCV pseudoparticles (HCVpp) or by cell-culture grown JFH-1-based HCV (HCVcc). A second PI4K-family member, PI4KIIIβ, also influenced cellular susceptibility to HCVpp infection and the ability of the cells to sustain HCV replication. These kinases may therefore represent new targets for HCV therapeutics.

The study is published in the FASEB Journal.

Bookmark It

Hide Sites

Related posts:

1. New (Host) Target for Treating HCV Hepatitis C virus (HCV) is one of the most important causes of chronic liver disease and infection can lead ultimately...
2. Blocking Host Target Stops Flu Nexbio have recently presented an update on their new, broad-spectrum candidate for the prophylaxis and treatment of flu, DAS181 (Fludase®)...
3. Renin Links CMV Infection to High Blood Pressure Human cytomegalovirus (hCMV) is a widespread member of the herpes family of viruses, with well over half of the world’s...
4. siRNA Experiments Identify Ebola Virus Drug Targets Antiviral drugs that exclusively target viral factors rather than host cell processes offer the possibility of fewer side effects but...
5. Virus-like Particles Protect against Chikungunya Virus Infection. Chikungunya is a viral disease spread by mosquitoes which causes fever and severe joint pain – the name derives from...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Thursday, July 23rd, 2009 at 8:30 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.